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Human T  ceils are characterized by their ability to form spontaneous rosettes with 
sheep erythrocytes (E) 1 (1-5).  This property is currently used  to enumerate T  cells 
because it is restricted to these cells.  Yet it is still  poorly understood. It appears to be 
a complex phenomenon, depending exquisitely on certain requisites of the procedure 
used, for example, temperature and time of cells' coincubations and pretreatment of 
E with various chemical compounds, so that the T lymphocyte population marked by 
this phenomenon will critically depend upon the conditions followed during the assay 
used  to  prove it.  For instance,  pretreatment  of E  with  neuraminidase  or  2-amino- 
ethylisothiouronium bromide (AET) will permit the detection of the largest popula- 
tion of T  cells,  whereas interaction with E  at 37°C will permit only the detection of 
thymocytes, or T  lymphoblasts (5-12). 
Recently (13),  a monoclonal antibody (MAb) termed 9.6 was obtained, which has 
permitted the identification of a T  lymphocyte surface molecule necessary to permit 
their  interaction  with  E.  We  have  obtained  another  MAb,  termed  anti-D66  (14), 
which identifies an epitope that also appears, as demonstrated here, to be involved in 
E-rosette formation. By contrast to 9.6, anti-D66 does not block rosettes when E have 
been pretreated with neuraminidase or AET, although it blocks E-rosettes made both 
at 4°C and 37°C. Thus, anti-D66 is extremely useful for investigating the phenomenon 
of E-rosette formation. 
* Supported by Association pour le D~veloppement de la Recherche sur le Cancer, Institut Gustave 
Roussy 8205, and VER Kremlin-Bic~:tre 832. 
1  Abbreviations  used in this paper:  AET,  2-amino-ethylisothiouronium  bromide; ALL,  acute lymphoblastic 
leukemia; BFUE, erythroid burst-forming unit cells; CFUC, colony-forming  unit cells; CLL, chronic 
lymphocytic leukemia; Con A, concanavalin A; E, erythrocytes; E+-PBL, peripheral blood lymphocytes 
forming E-rosettes; Fab-Mlg, Fab fragments ofimmunoglobulin  anti-mouse immunoglobulins; GMIg,  goat 
immunoglobulin anti-mouse immunoglobulins; LL, lymphoblastic lymphoma; MAb, monoclonal anti- 
body; PBL, peripheral blood lymphocytes; PBS, phosphate-buffered saline; SACI, Staphylococcus aureus 
Cowan I; S6z, S6zary. 
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We  demonstrate  here  that,  on  the  thymocyte  surface,  D66  and  9.6  epitopes are 
carried by the same molecule;  we also show  that,  although  9.6  epitopes are readily 
exposed on  the cell surface,  a  large fraction  of the  D66  epitopes is covered  by the 
glycocalixte from which it can be unmasked by anti-D66 sensitization plus anti-mouse 
immunoglobulins (Ig). Our observations offer a view on the respective roles of 9.6 and 
D66  epitopes in  determining the conditions of interactions  between  T  cells and  E. 
Extending  these  observations  to  malignant  T  cells  populations,  this  view  would 
account  for  the  "aberrations" observed  in  the  E-rosette-forming properties of these 
populations (14,  15). 
Materials and  Methods 
Preparation and Characterization of Monoclonal Antibodies.  Mice from the high responder strain 
selected by Dr. G. Biozzi (16) were immunized with a single intravenous injection of 5 ×  107 
thymocytes collected from a child undergoing cardiac surgery. 4 d later, spleen cells were fused 
with cells from the MOPC 21 NS1/1 plasmocytoma cell line, as previously described (16). The 
supernatants  were  screened  on  a  panel  of various  lymphoid  cells  using  a  C'-dependant 
microcytotoxicity assay (17).  Hybrids were serially cloned four times using a limiting dilution 
method.  Class and  subclass of the antibody were  assessed by immunodiffusion with  rabbit 
antisera (Litton Bionetics Inc., Kensington, ME)) and proved to be an IgG2b molecule. Hybrid 
cells were innoculated intraperitoneally into nude mice raised under sterile conditions. Ig were 
concentrated from the ascites by ammonium sulphate precipitation (40% saturation at 0°C), 
followed by washing, and desahed either by dialysis or by chromatography (ACA-202; IBF- 
Pharmindustrie, Villeneuve-La-Garenne, France). The amount of antibody was measured by 
immunodiffusion  and  compared  with  the  total  protein  content,  as  assessed  by  the  Fotin- 
Ciocalteu method. Next, biotin was fixed to Ig according to the general procedure described in 
ref.  18.  The  Ig solution  was  adjusted  to  I  mg/ml  in  0.2  M,  pH  8.8  bicarbonate  buffer, 
containing 0.15 M sodium chloride. 2 mg of N-hydroxysuccinimide  biotinate (Act-Biotine; IBF- 
Pharmindustrie)  was  dissolved in  0.5  ml  of anhydrous N-methylformamide. 200  /~1  of Act- 
Biotine was stirred into this solution and maintained for 15 min at 20°C. Next, 100/tl of 0.1 M, 
pH 6.0 ammonium chloride was added, and the preparation was desalted by chromatography. 
Preparation and characterization of 9.6 antibody used in the present investigation have been 
described by Malek et al. (13).  Preparation and characterization of rabbit anti-human T  cell 
antisera were extensively described elsewhere (19). 
Cell Preparations.  Mononuclear cells were obtained from peripheral blood (PBL) by Ficoll- 
Hypaque density centrifugation. Cells forming rosettes with sheep erythrocytes (E+-PBL) were 
isolated after removing plastic adherent and iron particles phagocytosing cells by rosetting with 
EAET (see  below)  and  centrifuging on  Ficoll-Hypaque. E-  cell  fraction  was  taken  as  the 
supernatant cell fraction after two sequential Ficoll-Hypaque centrifugations of PBL allowed 
formation of rosettes with EAET. 
Thymocytes were obtained from children undergoing cardiac surgery, from bone marrow 
normal healthy volunteers, for the purposes of allogenic bone marrow grafts, and from lymph 
nodes and spleens from cadaveric kidney donors. Cells were dispersed and prepared as described 
above. 
Malignant lymphoid cells were obtained from peripheral blood, lymph nodes, or pleural 
effusions. Specimens retained for investigation contained >83% malignant cells, as assessed by 
morphological criteria (20).  Procedures for cell prepations and  cryopreservations have been 
described elsewhere (21). 
Serological Analysis.  Reactivity of anti-D66 MAb with cells was assessed using a complement- 
dependent microcytotoxicity assay. It was also assessed by microfluorometry using a cytofluo- 
rograf (system 30  L; Ortho Instruments Co., Westwood, MA). Unless otherwise stated, cells 
were incubated for 10 min at room temperature with an excess amount of anti-D66 preparation 
in phosphate-buffered saline (PBS), containing 0.2%  sodium azide. The second reagent used 
was a fluorescinated goat F(ab')2 anti-mouse IgG (Tago Inc., Burlingame, CA), tested for its 
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Alternatively, a proper dilution of biotinylated anti-D66 preparation in 0.2% PBS-azide was 
incubated with cells at room temperature for 15 min. After washing the cells, excess amounts 
of fluorescinated-avidin  (IBF-Pharmindustrie) were added, and cells were incubated for 20 min 
at room temperature followed by three washes  in PBS-azide. 
In each experiment, controls included the same cell preparation sensitized with an irrelevant 
IgG2b MAb, followed by incubation with the second reagent. 
E-rosette Formation.  E were collected weekly  and kept in Alselver solution. After extensive 
washings with  PBS,  E  were  treated  with  AET  (Sigma  Chemical  Co.,  St.  Louis,  MO)  or 
neuraminidase (Behringwerke AG, Marburg, West Germany), as previously described (8, 10). 
The detailed procedures for E-rosette formation at 4°C, 37°C, and "active E-rosette tests" 
were  described in detail elsewhere  (2, 22, 23). In blocking experiments, cells were incubated 
with the appropriate dilution of MAb, washed twice in PBS-containing  bovine serum albumin, 
and assessed for rosette formation. Numerous checks were made using irrelevant MAb of the 
same subclass reacting with the lymphocyte surface; these did not induce rosette inhibition. 
Isolation and Characterization of Cell Surface Molecules.  Cells from HDMAR or KE37 lines were 
labeled by overnight incubation with [35S]methionine (CEA, Gifsur Yvette, France) (1 mCi of 
[aSS]methionine by 5 ×  10  7 cells incubated in 10 ml of methionine-free medium). Labeled cells 
were lysed by incubation for 45 rain at 0°C with 0.5% Nonidet P40 in 10 mM Tris HCI, pH 
8.0,  10  mM  iodoacetamide, 2  mM  phenylmethylsulfonyl chloride buffer. The lysates  were 
centrifuged at  10,000 g for 3 rain before storage at -70°C and recentrifuged upon thawing. 
Before use in immune precipitation analysis, the lysates were sequentially allowed to react with 
normal rabbit sera and fixed Staphylococcus aureus Cowan I  (SACI)  and next with rabbit anti- 
mouse IgG2b and SACI. Immunoprecipitations  were performed by coincubations of cell lysates 
with D66 or 9.6 for 30 min, followed by addition of SACI previously reacted with saturating 
amounts of R-MIg2b. After 15 min, the immune complexes were extensively washed in NaCI, 
EDTA, and Tris buffers and dissociated as described elsewhere  (47). Finally, supernatants were 
analyzed on a 30-cm long, 7.5  15% gradient of acrylamide gel containing 0.1% SDS. Fluorog- 
raphy was carried out as described (48), using Kodak RPX-O-mat films (Eastman Kodak Co., 
Rochester, NY) at -70°C. 
Results 
The Cellular  Distribution  of D66 Epitope among Leukocytes.  Fig.  1 shows the density of 
D66  antigen on  T  cell  populations, as  measured  by  flow-cytometry. Thymocytes, 
peripheral blood T  cells (E+-PBL), and T  lymphoblasts all gave a  single peak on the 
fluorescence histogram, but  it  is clear that  the  density of D66  varies among these 
populations;  it  was  high  on  thymocytes and stimulated T  cells,  particularly with 
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Fro.  1.  Fluorescence histograms obtained with various normal T cells populations labeled with 
anti-D66 plus fluorescinated  goat anti-mouse Ig. Similar results  were obtained using a biotine-avidin 
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TABLE  I 
D66 Distribution  among Leukocytes 
Cell populations 
C'-dependent* 
cytotoxicity  Percent of rec- 
assay  ognized cells 
Immunofluorescence assay~ 
Intensity§ 
Thymocytes  100  100  +++ 
E+-PBL  100  100  + 
E--PBL  0  0  0 
Granulocytes  0  NTI]  NT 
E- bone marrow cells  0  0  0 
E  + spleen cells  100  NT  NT 
E- spleen cells  0  NT  NT 
E  ÷ lymph nodes cells  100  NT  NT 
E- lymph nodes cells  0  NT  NT 
E  + tonsil cells  40.60  100  ++ 
E- tonsil cells  0  0  0 
E ÷ adenoid cells  40.60  100  ++ 
E- adenoid cells  0  0  0 
B CLL cells¶  0/5  0/5  0 
B cell lymphomas¶  0/6  0/6  0 
Non-T lymphoid cell lines¶**  0/8 
Non-T non-B ALL¶  0/15 
Acute myeloblastic leukemia¶  0/5 
0/8  0 
0/15  0 
0/15  0 
* Percent of destroyed  cells. 
1: Performed by flow cytometry as described  in Materials and Methods. 
§ See also Fig.  1. 
]1 Not tested, 
¶ Number of positive cases per number of tested cases. 
** The following cell lines were investigated:  Daudi, Raji, 8866, Ramos, NALM 6, 
NALM 16, K562, and Reh 6. 
concanavalin  A  (Con  A)  and  very low on  E+-PBL.  It  is worth  noting that,  as shown 
in Fig.  1, the density of D66 on thymocytes and, to a  lesser extent, on E+-PBL, greatly 
increased after these cells were treated with neuraminidase.  The mean density of D66 
on the surface of E + cells from tonsils and adenoids appears  to be closer to the values 
observed with thymocytes or stimulated  T  cells than  of peripheral  blood T  cells. 
Anti-D66  is  strongly  cytotoxic  with  complement.  In  Table  I,  it  can  be  seen  that 
anti-D66  plus  complement  destroys  all  the  cell  populations  displaying  D66  in  flow 
cytometry, including populations with very low density. This is also true for malignant 
T  cell populations  (Table V).  However, tonsil and  adenoid T  cells appeared  difficult 
to  destroy;  when  we  treated  PBL  with  anti-D66  plus  complement,  we  no  longer 
observed  a  mitogenic  response  to  phytohemagglutinin  (PHA),  Con  A, or  allogeneic 
cells, nor could we observe the generation of specific cytotoxic T  cells. At the effector 
phase,  these  cells  were  also  eliminated  by  anti-D66  plus  complement  (results  not 
shown). 
In  the  bone  marrow,  a  minor  subpopulation  appeared  to  display  D66  antigens, BERNARD ET AL.  1321 
which  disappeared  after removal of E-RFC  or killing cells  with  hetero-anti-T  cell 
antiserum plus complement (see Table I). To assess whether D66 would be carried by 
precursor  hematopoietic  cells,  we  studied  whether  colony-forming  unit  cells  and 
erythroid burst-forming unit cells would be eliminated by anti-D66 plus complement. 
No effect was observed on the  number of growing colonies after such  a  treatment 
(results not shown).  D66 antigen was not detectable on normal B cells from various 
organs as well as monocytes and granulocytes, nor was it detectable on B cell lines or 
on the cells from the various myeloid, non-T non-B, and B lymphoid malignancies we 
studied  (see Table I). Thus, D66 epitope, among leukocytes, appears to be restricted 
to T  cells.  Moreover,  the  D66  molecule  is  actually  synthetized  by T  cells  because 
destruction of D66 with pronase was followed by in vitro resynthesis. We performed 
this experiment both with normal T  cells and with a T  cell line (results not shown). 
Blocking E-Rosette  Formation with Anti-D66.  As shown  in  Fig.  2,  we observed that 
precoating T  lymphocytes with anti-D66 inhibited  E-rosette formation both at 4°C, 
37°C, and after the procedure of active E-rosettes (2, 23)  in a dose-dependent manner 
until  completely  inhibited.  However, we  observed  that  anti-D66  had  no  blocking 
effect  when  E  were  pretreated  with  AET  or  neuraminidase.  We  observed  these 
blocking patterns  of anti-D66  on  E-rosette  formation of E+-PBL,  thymocytes, and 
mitogen-stimulated  lymphoblasts.  Interestingly,  when  we  stimulated  T  cells  with 
mitogens,  their  D66  surface  density  increased  simultaneously  with  their  ability  to 
form stable E-rosettes at 37°C  (Table II). 
We next investigated whether the D66 epitope would  be directly involved in the 
interactions  between  E  and T  cells by capping experiments. As anti-D66  alone did 
not  induce  capping, we added  a  goat  anti-mouse Ig (GMIg). Table III shows  that 
after we induced an almost complete loss of D66 from the T  cell surface, they were no 
longer able to form rosettes with E, both at 4°C and 37°C.  This could be achieved, 
however, according to the experiment, after at least three successive steps of capping 
procedure  (i.e.,  successive  addition  of anti-D66,  GMIg and  incubation),  when  we 
observed a  significant decrease in D66 density on the cell surface in flow-cytometry, 
and it took six successive cycles before D66 density would reach very low values (Fig. 
3, E and F). In a parallel manner, the ability ofT cells to form E-rosettes at 4°C and 
37°C decreased with successive capping (Table III). 
Unmasking Hidden  D66.  Surprisingly,  after a  single cycle of capping with GMIg, 
and despite the observation of a  bright  fluorescent cap, rosette inhibition  produced 
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Flc.  2.  Inhibition  of E-rosette formation by increasing amounts of anti-D66. (+) EAET rosettes; 
(l~) E-rosettes  at 4°C; (A) E-rosettes at 37°C; and (9#) "active" E-rosettes. 1322  HUMAN T  CELL  ROSETTING ANALYZED WITH  MONOCLONAL  ANTIBODIES 
TABLE  II 
Kinetics of Variations in D66 Densities on the Surface of T  Cells after 
Mitogenic Stimulation 
Percent E.RFC at  Hours  D66 surface density*  37oc  § 
PHA~ 
0  +  30+9 
12  ++  60 +  10 
24  +++  76 +_ 7 
48  +++  85 +  7 
72  +++  87 + 6 
Con A:~ 
0  +  30 +  10 
12  +++  90 +_ 10 
24  ++++  95 +  7 
48  ++++  92 + 6 
72  ++++  92 +-- 5 
++++ 
* Measured  by flow fluorometry;  +,  density  analogous  to  E±-PBL; +++, 
density analogous to thymocytes (see Fig. 1). 
:~ 105 cells were cultivated in 200 #1 of RPMI-FCS containing  the optimum 
dilution of PHA (Wellcome Laboratoires, Beckenham, England) or Con A 
(Sigma Chemical Co., St. Louis, MO.) 
§ Rosette-forming cells 
by anti-D66 was completely raised (Table III and Fig. 4). To further investigate this 
phenomenon,  we  first  used  an  Fab  fragment  of a  rabbit anti-mouse  Ig  (Fab-MIg). 
Again, as shown in Table III, with a single addition of Fab-MIg on anti-D66-sensitized 
T  cells, rosette inhibition was raised. Control tests done in fluorescence assay showed 
that  the  amount  of  Fab-MIg  added  could  totally  inhibit  subsequent  binding  of 
fluorescent  GMIg  (Fig.  3B).  Yet,  on  cells sensitized with  anti-D66  plus  Fab-MIg, 
subsequent  incubation with anti-D66  revealed that  a  large number  of D66  epitopes 
could then be detected on the whole cell surface (Fig. 3 C). Thus,  binding of an Fab 
fragment or of whole molecules of anti-mouse Ig to anti-D66 fixed to the cells induced 
the appearance of large amounts  of D66  epitopes not  readily accessible on  the cell 
surface. Most probably these additional epitopes allowed T  cells to reform E-rosettes. 
Such  a  phenomenon--unmasking  D66  not  readily accessible on  the cell surface, 
induced  by  fixation  of GMIg  or  Fab-MIg on  anti-D66--could  not  be  blocked,  as 
shown in Table III and Fig. 3 C', by cytotalasin B up to a  concentration of 100 g/ml, 
by incubation at 4°C,  or in sodium azide (0.2%)  alone. It was only by maintaining 
the T  cells both at 4°C  and in the presence of sodium azide, after sensitization with 
anti-D66, that further addition of anti-MIg no longer raised the blocking the E-rosette 
formation, nor induced unmasking of D66 as revealed by flow cytometry (Fig. 3 C"). 
Since  observing  that  neuraminidase  unmasked  large  quantities  of  D66  on  the 
thymocyte surface, we wondered whether  the effects of anti-MIg on  anti-D66-sensi- 
tized thymocytes would be raised or reduced after pretreatment with neuraminidase. 
From Table III, it can be seen that either GMIg or Fab-MIg had a  reduced effect on 
the  inhibition  of E-rosette  formation  induced  by  anti-D66  on  neuraminidase-pre- 
treated  thymocytes;  from  Fig.  3G,  it  can  be seen  that  the  fluorescence intensity of BERNARD ET AL. 
TABLE III 
Anti-D66, Anti-Mouse Ig, Fab Anti-Mouse Ig, and the Inhibition orE-Rosette  Formation of 
Neuraminidase-treated or Nontreated Thymocytes  * 
1323 
Cell sensitization 
Untreated thymocytes  Neuraminidase-treated thymocytes 
E 37°C  E 4°C  EAET  E 37°C  E 4°C  EAET 
Medium  93  96  95  96  98  95 
Anti-D66  1  12  95  5  18  96 
Anti-D66 + GMIg  87  89  NT:]:  35  45  NT 
Anti-D66 + Fab-MIg  92  98  NT  27  39  NT 
With cytochalasin B 
Anti-D66 + ~MIg  89  90  NT  NT  NT  NT 
Anti-D66 + Fab-MIg  88  86  NT  NT  NT  NT 
At 4°C + PBS-Az 
Anti-D66 + GMIg  NT  63  NT  NT  16  NT 
Anti-D66 + Fab-MIg  NT  56  NT  NT  18  NT 
Successive sensitizations 
(Anti-D66 + GMIg) X 3  51  76  NT  NT  NT  NT 
(Anti-D66 + Fab-MIg) X 3  48  62  NT  NT  NT  NT 
(Anti-D66 + GMIg) X 6  24  51  85  I2  35  95 
(Anti-D66 + Fab-MIg) X 6  18  48  92  7  42  91 
(Medium + GMIg) × 6  92  87  89  95  87  86 
* Results expressed as percent of E-rosette-forming  cells. 
:~ Not tested. 
anti-D66-1abeled cells was readily maximal, and further addition of anti-D66 did not 
result in an increase in fluorescence. 
The  Relationship  of D-66  Epitopes  with  9.6  Epitopes.  9.6  is  an  MAb  obtained by 
Kamoun et al. (13), which has been shown to block E-rosette formation. In addition, 
the 9.6 epitope was shown to be involved in the interactions between E and T  cells by 
lysostripping experiments (13).  We have thus investigated the relationship between 
the  epitopes  defined  by  9.6  and  anti-D66.  Several  major  differences  immediately 
became apparent: (a)  9.6 could block rosette formation with E  pretreated with AET 
as effectively as it could block rosette formation with nontreated E; (b) on a weight for 
weight basis, 9.6 was much more efficient in blocking E-rosette formation than was 
D66;  and  (c)  in contrast with  D66,  the  density of 9.6  on  E+-PBL  is  similar to  its 
density on thymocytes (results not shown). 
Second, we looked to see whether 9.6 could block subsequent fixation of anti-D66 
and  vice  versa.  Fig.  5  clearly  shows  that  no  cross-blocking occurred  between  the 
fixation of anti-D66 and 9.6 to thymocytes, demonstrating that they react with two 
different epitopes. 
Third, are  D66 and 9.6 epitopes linked on the cell surface? We investigated this 
point in a series of cocapping and lysostripping experiments. The results are displayed 
in Table IV.  It  is clear that  when we used 9.6  as  the  first  antibody to  induce cap 
formation on thymocytes, the capped cells could no longer be restained or destroyed 
by anti-D66. When we used anti-D66 as the first antibody to induce cap formation, 1324  HUMAN  T  CELL  ROSETTING ANALYZED  WITH  MONOCLONAL  ANTIBODIES 
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Flc.  3.  Fluorescence histograms obtained after various procedures of thymocytes sensitization with 
whole anti-mouse Ig or a Fab fragment. 
most of the cells were restained by anti-D66 and 9.6. However, their susceptibility to 
lysis by anti-D66 as well as 9.6 was greatly decreased, whereas little effect was observed 
on their ability to be killed by an irrelevant MAb. 
Fourth,  are D66 and 9.6 carried by the same molecule? We demonstrated this by 
sequential radioimmunoprecipitations, using radiolabeled T  cell lines. From Fig. 6, it 
is clear that both 9.6 and anti-D66 precipitated a single polypeptide of =50,000  mol 
wt.  In addition,  sequential  precipitations with anti-D66 followed by 9.6 or with 9.6 
followed by anti-D-66 showed that the same polypeptide is indeed recognized by both 
antibodies. 
Correlations  between  9. 6  and D66 Surface  Densities of T  Lymphobtastoid  Cells and  Their 
Abilities to Form E-Rosettes.  The correlation between D66 surface densities of normal 
T  cells  and  their  ability  to  form stable  E-rosettes  at  37°C  led  us  to  investigate T 
lymphoblastoid cells either in  long-term culture or from specimens freshly collected 
from patients. All the lymphoblastoid cell populations we investigated were differen- 
tiated within the T  cell axis because they reacted with several anti-T cell antisera (19) 
and  MAb-defining  epitopes  considered  to  be T  cell  specifics and  lacking  markers 
found on B or non-T non-B lymphoid cells. The results were clear-cut: 9.6-, D66- cell BERNARD  ET  AL.  1325 
Fro.  4.  Rosette formation at 37°C between untreated E and thymocytes sensitized with anti-D66 
followed by fluorescinated anti-mouse Ig and allowed to cap. The amount of anti-D66 used would 
totally inhibit E-rosette formation when used alone. 
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FIe.  5.  Fluorescence histograms obtained after labeling thymocytes with 9.6.  and fluorescinated 
protein A  (anti-D66 do not fix protein A) and/or biotinylated anti-D66 plus fluorescinated avidin. 
populations did not form E-rosettes, either with EAET or with non-treated E. Only cell 
populations displaying high D66 surface densities formed E-rosettes stable at  37ac. 
9.6  +, low surface density D66 lymphoblastoid cells  formed significant amounts of E- 
rosettes stable at 4oC; finally, 9.6  +, D66- cells  only formed rosettes with EAET. It is 
notable that we did not find any 9.6- D66  + cell population. However, we did find a 
few cases with 9.6  + cells  that did not form rosettes with EAET and that could not be 
included in the present study because of lack of cells. 
Could some D66- or low D66 surface density lymphoblastoid cells  have  hidden 
D66  epitopes?  As  indicated  in  Table  V,  we  treated  cells  from  four  patients  with 
neuraminidase. Three patients had 9.6  +, low density D66 cells.  After neuraminidase 1326  HUMAN T  CELL  ROSETTING ANALYZED WITtt  MONOCLONAL ANTIBODIES 
TABLE  IV 
Cocapping and Lysostripping  of 9. 6 and D66 on Thymocytes * 
First 
antibody 
Percent  of cells  Percent of 
Percent cells  capped by the 1st Ab  restained  by the  cells capped 
Percent  cells  stained but not  Second antibody  2nd Ab  by the 1st Ab 
forming cap  capped with  lysed after 
with 1st Ab 
1st Ab  1st cycle  2nd cycle  adding 2nd 
Ab +  C'  capping  capping 
9.6  52±  I0  20±4 
Anti-D66  39 +  7  29 _  5 
9.6  l0  4  6 
Anti-D.66  30  11  l0 
W6.32:~  43  40  28 
Anti-D66  80  50  9 
9.6  80  61  7 
W6.32  80  80  26 
* Thymocytes were incubated for 20 min with an excess amount of the 1st MAb. After washings, thymocytes 
were incubated for 45 min at 37°C with an excess amount of fluoresceinated  goat anti-mouse Ig (one 
cycle).  After further washings,  they were incubated  for 5 min at  room temperature with pure mouse 
ascites  induced by MOPC 21  NSI/I plasmocytoma cell line. They were next incubated for 30 min at 
room temperature with an excess amount of the 2nd  MAb. After washings,  they were incubated for 30 
min at room temperature with an excess amount of TRITC-F(ab')2 goat-anti-mouse Ig. For lysostripping 
experiments, the capping cycle  was  performed as  described  above. The cells were then  processed  as 
described  in ref. 43. 
~: W6.32 is a monomorphic anti-HLA MAb. 
treatment,  D66  density  increased  as  these cells acquired  the  property  to  form  37°C 
stable  E-rosettes.  One  patient  had  9.6-,  D66-  cells.  After neuraminidase  treatment, 
D66 and  9.6 densities did not  increase,  nor did these cells acquire the ability to form 
E-rosettes. 
Discussion 
The major conclusion of our present study is that  D66 is an epitope involved in the 
interactions  between  T  lymphocytes  and  E.  First,  we observed  that  anti-D66  is able 
to block E-rosette  formation  both  at  4 °  and  37°C  in a  dose-dependent  manner  until 
complete inhibition.  However, when  E  were pretreated  with AET  or neuraminidase, 
we  observed  no  blocking  effect  regardless  of  the  amount  of  anti-D66  we  added. 
Second,  after we could  induce  an  almost  complete  displacement  of D66  on  the  cell 
surface,  the  T  cells lost  their  ability  to  form  E-rosettes.  Thus,  the  D66  epitope  or  a 
closely  related  epitope  carried  by  the  same  molecule  is  directly  involved  in  the 
interactions between T  cells and  E. 
This epitope is clearly different  from the epitope defined by the MAb  9.6 obtained 
by  Kamoun  et al.  (13).  We observed  no cross-blocking  between  the  fixation  of anti- 
D66  and  9.6.  Yet, both  epitopes are carried  by the same molecule of 50,000  mol wt, 
as  revealed  by  sequential  immunoprecipitation  assays  on  two  different  T  cell  lines. 
On  thymocytes,  also,  the  majority  of both  epitopes  appeared  to  be  carried  by  the 
same  molecule,  as  this  is  consistent  with  the  results  of cocapping  and  lysostripping 
experiments.  In  addition,  a  large  fraction  of D66  was  hidden  (Fig.  7)  or  prevented 
from  reacting  with  anti-D66  by  sialic  acid,  whereas  neuraminidase  treatment  of T 
cells  produced  no  change  in  reactivity  with  9.6.  Although  we  shall  further  discuss BERNARD  ET  AL.  1327 
FIG. 6.  Radioimmune  precipitation assays with  9.6. and  anti-D66  of the  leukemic  cell  line 
HDMAR. Cells were radiolabeled with [zSS]methionine  and immunoprecipitated as indicated in 
Materials and  Methods.  Analysis was performed  by sodium  dodecyl sulfate-polyacrylamide  gel 
electrophoresis. The positions of migration of the molecular weight markers are indicated by arrows. 
(A) immunoprecipitation  with anti-D66; (B) anti-D66 after a first precipitation with anti-D66;  (C) 
immunoprecipitation  with  9.6. after precipitation with  anti-D66;  (D) immunoprecipitation with 
9.6.; and (E) immunoprecipitation  with anti-D66 after precipitation with 9.6. Identical results were 
obtained using another cell line (KE 37). 
evidence for D66  being a  hidden epitope, such concealed structures on lymphocytes 
have been clearly demonstrated  (28, 29). 
As on  E+-PBL,  the  D66  density is much  lower than  on  thymocytes, even  though 
the ceils have been treated with neuraminidase; and as 9.6 surface density on E+-PBL 
is similar to 9.6  density on  thymocytes, it  is likely that  many  9.6  +, D66-  molecular 
variants would be present on E÷-PBL. However, the entire population of peripheral 
T  cells displays both 9.6 and D66, as this is apparent  from fluorometer histograms. 
We observed a  striking correlation between the surface density of D66 of a  given T 
cell population and  its ability to  form stable rosettes at  37°C.  Thus,  D66  density is 
high  on  the  surface  of the  vast  majority  of thymocytes,  T  cells  from  tonsils  and 
adenoids, T  lymphoblasts after allogeneic stimulation or stimulation with PHA, and, 
significantly more,  after  stimulation  with  Con  A.  All these  T  cell populations  are 
known to form stable E-rosettes at 37°C  (30, 37). Moreover, the kinetic of increase in 1328  HUMAN  T  CELL  ROSETFING  ANALYZED  WITH  MONOCLONAL  ANTIBODIES 
TABLE  V 
Comparisons between the Abih'ty of T Lymphoblastoid Cell Populations to Form Various Types of 
E-Rosettes and Their Surface Densities in 9.6 and D66 Epitopes 
Lymphoblastoid 
cells* 
E-rosette~ formation  Reactivity with MAb§ 
EAET  E4  E  37°C  %6  D66, fluores-  C' cytotox- 
ceinated  icity 
Cell lines 
HDMAR  90  71  51  +++  +++  + 
KE37  95  92  60  ++  ++  + 
JM  40  37  0  ++  -  + 
MOLT4  5  0  0  -  -  - 
CEMT  0  0  0  -  -  - 
HSB2  22  1  0  -  -  - 
Peer  12  0  1  -  -  - 
T  cell malignancies 
T-LL1  91  90  61  +++  ++  + 
T-LL2  85  80  66  ++  +++  + 
T-LLz  91  91  7 l  ++  +++  + 
T-LL4  92  79  89  ++  ++  + 
T-LL5  97  78  84  ++  ++++  + 
T-ALL1  80  56  31  +++  +  + 
T-LL6  80  54  15  ++  -  + 
S6z~  70  40  8  +++  -  + 
T-ALL2  75  NT[[  <  1  +++  -  + 
T-LL7  74  22  <1  ++  -  + 
$6z2  58  19  13  +++  -  + 
T-LL~  22  11  <1  +  -  --- 
T-ALL3  8  4  <  i  -  -  - 
T-ALL  10  <1  <1  -  -  - 
T-ALL5  7  <  1  <  !  -  -  - 
T-ALL6  <  1  <  1  <  1  -  -  - 
After neuraminidase treatment 
T-LL6  84  78  49  ++  +  NT 
$6zl  82  56  36  +++  +  NT 
$6z2  70  40  19  +++  +  NT 
T-ALL3  7  4  <  1  -  --  -- 
* 9.6-,  E-  lymphoblastoid cell  populations  were  classified as  T  cells because  they  reacted  with  several 
hetero-anti-T cell antisera (19) and monoclonal antibodies defining T  cell specific epitopes. For instance, 
T-ALL 3-6 had cells that reacted with anti-T6 (24) and D47 (25) and 3AI  (26); they lacked cytoplasmic 
or surface Ig, HLA-DR,  nor did they react with anti-Bl MAb (27). 
:~ Percent of E-rosette-forming cells morphologically identified after sedimentation and Wright's staining. 
§ 9.6,  +++  is the density on both  thymocytes and  E+-PBL;  D66,  +++  is the density on  thymocytes;  +, 
density on E+-PBL. 
II Not tested. 
D66  densities  on  the  surface  ofT  cells after  mitogenic  stimulation  was  identical  to  the 
kinetic  of increase  in  their  ability  to  form  37°C  stable  E-rosettes.  Similarly,  treatment 
of E+-PBL  with  an  appropriate  amount  of neuraminidase  increased  both  the  density 
of D66  and  the  number  of 37°C  stable  E-rosettes  (8).  Limited  enzymatic  destruction 
decreased  D66  surface  density  and  the  thymocytes'  ability  to  form  37°C  stable  E- 
rosettes  in  a  parallel  manner.  More  strikingly,  we  investigated  7  T  lymphoblastoid FIG.  7. 
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cell lines in long-term culture and 16 cases ofT lymphoid malignancies and compared 
their  surface densities  in  9.6 and  D66 epitopes with  their aptitude  to form rosettes 
with EAET and untreated E at 4°C and at 37°C. The results we obtained were clear- 
cut: we found no lymphoblastoid T  cell population displaying D66 that did not also 
display 9.6.  The T  lymphoblastoid cell populations displaying 9.6 and low densities 
of D66 formed rosettes with EAST or, to a lesser  extent, with untreated E at 4°C, but 
no significant number of E-rosettes at 37°C. The T  lymphoblastoid cell populations 
that carried high densities of both D66 and 9.6 formed stable rosettes at 37°C. 
Therefore, it is possible to see the T  cell surface structure responsible for interacton 
with E  as follows: the 9.6 epitope is necessary for stable interaction between T  cells 
and  E.  When  E  are  pretreated  with  AET  or  neuraminidase,  such  interaction  is 
sufficient to permit rosette formation and stability, regardless of temperature, either 
because  the  number  of structures  interacting  with  9.6  on  the  E  surface  has  been 
increased or because they have been modified so that the affinity of interaction would 
have increased. When E are not treated,  the D66 epitope is also required for rosette 
formation. The interaction  between  D66  and  anti-D66 structure  on  E  would have 
maximum affinity at 4°C, so that when the density of D66 is low, rosette stability is 
ensured only at  4°C.  In contrast, when D66 density is high, rosette stability is also 
ensured at 37°C. On the thymocytes and T  blast surfaces, most of the molecules carry 
both D66 and 9.6, whereas on E+-PBL, most of the  molecules would carry the 9.6 
epitope only. 
In no way do we pretend that this view could account for all the events leading to 
rosette formation: most probably other structures, possibly other molecules, should be 
involved in interactions between E and T  cells,  as,  for instance, the active E-rosettes 
test appears to mark a population differing from the E-rosettes obtained at 37°C (2, 
23); yet, both assays are blocked by 9.6 and anti-D66. It is also noteworthy that we 
could observe,  among T  cell  malignancies,  few cases with  cells  displaying 9.6,  but 
that were unable to form rosettes with EAST (these results could not be included in the 
present study because of lack of cells)  (14,  15). 
While  performing our  investigations,  we  were  surprised  by two phenomena:  (a) 
although  we  could  obtain  capping of D66  as  revealed  by  fluorescence  gathering, 
relabeling of the cells  with  anti-D66 showed that,  after such a  capping, important 
amounts of diffuse D66 were then present on the cell surface, and  (b)  blocking of E- 
rosette formation by anti-D66 was totally raised  after fixation of a  second antibody 
on anti-D66. Actually, an Fab fragment of anti-mouse Ig (Fab-MIg) could both raise 
the E-rosette inhibition produced by anti-D66 and induce further appearance of D66 
on the thymocyte surface. 
We found the effects of Fab-MIg to be  reminiscent  of TL molecule modulation, 
which can be induced by Fab fragments, and by which a cell can escape C'-dependent 
lysis,  although TL-anti-TL complexes are  still  present  on  the  cell  surface  (32-35). 1330  HUMAN  T  CELL  ROSETTING ANALYZED WITH  MONOCLONAL  ANTIBODIES 
This appears to be a  complex phenomenon,  involving several mechanisms, but  the 
basic event would  be a  microdisplacement  of TL molecules induced  by fixation of 
anti-TL Ig, even though  it would be limited to an Fab fragment (33).  Dealing with 
the  D66-carrying molecule, this  microdisplacement would  cause  further rearrange- 
ment of all these molecules, including those carrying hidden D66, perhaps because of 
their  involvement  in  complex  supermolecular  organization  on  the  cell  surface  (L. 
Boumsell and A. Bernard, manuscript in preparation). 
It  is  known  that  quite  a  number  of T  cell  malignancies  have  malignant  cell 
populations that do not form rosettes with E (21, 36, 37). Pretreating E with AET was 
shown to be the most efficient technique  for detecting the ability of a  malignant T 
cell population to form E-rosettes (38).  This inability to form E-rosettes was demon- 
strated for S~zary cells as well as leukemic and lymphomatous ceils, with character- 
istics of T  cells quite advanced along the T  cell maturation process, both in terms of 
surface  antigens  and  functions  (39-42).  We  show  here  that  the  treatment  of such 
malignant T  cell populations with neuraminidase uncovers in many cases the other- 
wise masked D66 epitope. This treatment also confers to these cells the ability to form 
rosettes with untreated E at 37°C. In other cases, particularly when the 9.6 epitope is 
not readily detectable, no D66 is uncovered after neuraminidase  treatment,  nor are 
these malignant cells conferred the ability to form E-rosettes. Thus, abnormalities of 
the  glycocalixte  of  malignant  T  cells  can  induce  abnormalities  of  their  surface 
antigenic phenotype. 
The events we have called D66 "modulation" on the thymocyte surface should be 
related  to  the  functional  role  of  the  molecule.  Thus,  modulation  of cell  surface 
structures  should  be a  widely shared  property of such  structures,  whose  triggering 
could  be  the  privilege  of preculiar  epitopes.  Although  having  large  physiological 
significance, such events could lead to escape of immune destruction when occurring 
on the surface of malignant cells (44-46). 
Summary 
Anti-D66  is a  monoclonal antibody able to inhibit  E-rosette formation of T  cells 
both  at  4°C  and  at  37°C  but  that  does  not  inhibit  T  cell  rosette  formation with 
neuraminidase  or  2-amino-ethylisothiouronium  bromide  (AET)-pretreated  E.  As 
demonstrated  by capping experiments,  it  defines  an  epitope,  D66,  that  is  directly 
involved  in  E-rosette  formation.  D66  is  distinct  from  the  epitope  defined  by  9.6 
because 9.6, a previously defined "pan-T" monoclonal antibody, inhibits EAET rosette 
formation and because no cross-blocking occured between both antibodies  fixation. 
However,  9.6  and  D66  are  carried  by  the  same  molecule,  as  demonstrated  by 
sequential  immunoprecipitation assays performed on two different  T  cell lines.  On 
the  thymoeyte surface,  also,  9.6  and  D66  are  most  probably carried  by  the  same 
molecule, as indicated by cocapping and colysostripping experiments. D66 is present 
at higher densities on thymocytes and activated T  cells than on peripheral blood T 
cells.  Investigation  of numerous  T  cell  populations,  both  normal  and  malignant, 
showed  a  straightforward  correlation  between  elevated  D66  density  and  ability  to 
form 37°C stable E-rosettes. Neuraminidase treatment of thymocytes and peripheral 
blood lymphocytes forming E-rosettes unmasked a  large fraction of D66 not readily 
accessible on their surface. These hidden D66 epitopes appear to be responsible for a 
surprising observation: the ability of anti-D66 to inhibit E-rosette formation could be BERNARD  ET  AL.  1331 
totally reversed by fixation on anti-D66 of an antibody to mouse immunoglobulin or 
an Fab fragment anti-mouse immunoglobulin. This would induce microdisplacement 
with  emergence  of  hidden  D66,  as  documented  by  fluorometric  studies.  Finally, 
malignant T  cells with a  differentiative status of mature T  cells, but forming no  (or 
low  numbers  of)  E-rosettes, could  be  induced  both  to  display D66  and  to  form  E- 
rosettes by neuraminidase treatment. 
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